MedTrace Logo

Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study

NCT01663129 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 406

Last updated 2018-07-20

No results posted yet for this study

Summary

To determine the magnitude and rate of bone mass deficits following initiation of glucocorticoid therapy for the treatment of pediatric leukemia, rheumatic conditions and nephrotic syndrome, we propose a 6 year, prospective study in 12 academic, tertiary care centres across Canada.

The investigators hypothesize that glucocorticoid-treated children with leukemia, rheumatic conditions and nephrotic syndrome will fail to accrue bone mass at a normal rate, and that deficits in mineral accrual will occur in a glucocorticoid dose- and duration-dependent fashion. We also hypothesize that the fracture incidence will increase with concomitant reductions in bone mass.

Conditions

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Children's Hospital of Eastern Ontario

    lead OTHER

Principal Investigators

  • Leanne M Ward, MD FRCPC · Children's Hospital of Eastern Ontario

Eligibility

Min Age
1 Month
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2014-03-06
Completion
2014-03-06

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01663129 on ClinicalTrials.gov